Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04068753 · ClinicalTrials.gov registry record · Phase 2
Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer
A Phase 2 study of Recurrent Cervix Cancer and Progressive Cervix Cancer, sponsored by University of Oklahoma.
- Active
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
- 4
- Study locations
NCT04068753: Active Phase 2 study of Recurrent Cervix Cancer and Progressive Cervix Cancer, sponsored by University of Oklahoma.
NCT04068753 is a Phase 2 study of Recurrent Cervix Cancer and Progressive Cervix Cancer that is active but no longer recruiting, run by University of Oklahoma. The registered enrollment target is 66 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04068753, a Phase 2 study of Recurrent Cervix Cancer and Progressive Cervix Cancer, is active but no longer recruiting, sponsored by University of Oklahoma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this research study is to test the safety of Niraparib and dostarlimab as a combination treatment and see what effects (good and bad) this combination treatment has on patients with recurrent or progressive cervix cancer.
Primary Outcome
The proportion of patients treated with Niraparib and dostarlimab who achieve CR or PR, evaluated using RECIST v1.1
Conditions Studied
Interventions
- DRUG Niraparib
- DRUG dostarlimab
Study Locations (4)
Indiana
- Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
Louisiana
- Louisiana State University Health Science Center - New Orleans
Oklahoma
- Stephenson Cancer Center - Oklahoma City
Virginia
- University of Virginia Cancer Center - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2020-02-26 |
| Est. Completion | 2027-07 |
| Phase | Phase 2 |
What the registry record for NCT04068753 still lists
NCT04068753 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower).
The record links to 2 conditions, with Recurrent Cervix Cancer appearing as the primary indexed condition, and to 2 interventions - of which Niraparib is the first listed.
NCT04068753 reports a single indexed study location in Indiana, Louisiana, Oklahoma.
Frequently Asked Questions
What is clinical trial NCT04068753 about?
NCT04068753 is a clinical study titled "Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer". The purpose of this research study is to test the safety of Niraparib and dostarlimab as a combination treatment and see what effects (good and bad) this combination treatment has on patients with recurrent or progressive cervix cancer.
What is the current status of trial NCT04068753?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2020-02-26. Estimated completion is 2027-07.
What conditions does trial NCT04068753 study?
This clinical trial studies the following conditions: Recurrent Cervix Cancer, Progressive Cervix Cancer.
What interventions are being tested in trial NCT04068753?
The interventions under investigation include: Niraparib (DRUG), dostarlimab (DRUG).
Who is sponsoring clinical trial NCT04068753?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04068753 being conducted?
This trial has 4 study locations across Indiana, Louisiana, Oklahoma, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04068753's enrollment target sits among peer trials
66 975th of 2000 higher than 1,014 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI